Breast Cancer | Clinical

Molecular Testing With Universal Method Comparable to Traditional Method in Hereditary Solid Tumors

November 17, 2020

In an interview with Targeted Oncology during the 2020 Association for Molecular Pathology Annual Meeting, Ozge Ceyhan-Birsoy, PhD, discussed genetic testing methods for patients with hereditary predisposition and the molecular research underway at MSKCC to improve testing in this patient population.

Palbociclib Demonstrates Prolonged OS/PFS When Initiated in Metastatic Breast Cancer

November 15, 2020

Patients who received palbociclib and fulvestrant before chemotherapy for metastatic breast cancer had greater clinical benefit versus patients who received placebo and fulvestrant, according to an exploratory subgroup analysis of the phase 3 PALOMA-3 trial.

Hormone Receptor, pCR May Point to Survival on Dual HER2 Blockade

November 11, 2020

Updated data reported from a phase 3 trial show that patients with HER2- positive early breast cancer had better rates of overall survival after experiencing a pathologic complete response on HER2-targeted therapy, and these responses were observed most often in those with hormone receptor–negative status.

TNBC Heterogeneity Opens Door for Emerging Targeted Therapies

October 26, 2020

As a greater understanding of triple-negative breast cancer heterogeneity develops over time, combinations of PD-1/PD-L1 plus PARP inhibitors, androgen receptor targeted agents, and PI3K/AKT/mTOR pathway inhibitors are undergoing evaluation by investigators in the field.

Expert Reviews Novel Strategies in the Pipeline for the Treatment of ER-Positive Breast Cancer

October 22, 2020

Recent acceleration in the introduction of new regimens for the treatment of estrogen receptor–positive breast cancer has led to significant survival enhancement, but questions remain regarding how patients should be stratified following disease progression with these therapies.

Investigators Tailor TNBC Therapy Using Genomic Alterations

October 21, 2020

In a presentation at the 2020 Lynn Sage Breast Cancer Symposium, Virginia G. Kaklamani, MD, DSc, reviewed the current genomic tools in the triple negative breast cancer landscape that predict response to targeted treatments.

Palbociclib Combination Misses Primary End Point of PENELOPE-B in HR+, HER2- Early Breast Cancer

October 09, 2020

Palbociclib in combination with standard endocrine therapy did not improve invasive disease-free survival in patients with hormone receptor-positive, HER2-negative early breast cancer who have residual invasive disease after completing neoadjuvant chemotherapy, missing the primary end point of the phase 3 PENELOPE-B trial.